Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 299

1.
2.

Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.

Chan WM, Lai TY, Liu DT, Lam DS.

Ophthalmology. 2007 Dec;114(12):2190-6. Epub 2007 Jun 28.

PMID:
17599414
3.

Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.

Iacono P, Parodi MB, Papayannis A, Kontadakis S, Sheth S, Bandello F.

Retina. 2011 Oct;31(9):1841-7. doi: 10.1097/IAE.0b013e31821800a4.

PMID:
21775926
4.

Macular functional changes evaluated with MP-1 microperimetry after intravitreal bevacizumab for subfoveal myopic choroidal neovascularization: one-year results.

Scupola A, Tiberti AC, Sasso P, Savastano MC, Mastrocola A, Marangoni D, Minnella AM, Falsini B, Balestrazzi E.

Retina. 2010 May;30(5):739-47. doi: 10.1097/IAE.0b013e3181c59725.

PMID:
20038860
5.

Intravitreal bevacizumab for extrafoveal choroidal neovascularization secondary to pathologic myopia.

Parodi MB, Iacono P, Papayannis A, Kontadakis S, Cascavilla ML, Zucchiatti I, Bandello F.

Retina. 2013 Mar;33(3):593-7. doi: 10.1097/IAE.0b013e31826b6731.

PMID:
23190919
6.

Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization.

Rouvas A, Petrou P, Douvali M, Ntouraki A, Vergados I, Georgalas I, Markomichelakis N.

Retina. 2011 May;31(5):871-9. doi: 10.1097/IAE.0b013e3182003ca8.

PMID:
21358461
7.

Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results.

Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB.

Am J Ophthalmol. 2009 Jan;147(1):84-93.e1. doi: 10.1016/j.ajo.2008.07.022. Epub 2008 Sep 6.

PMID:
18774547
8.

Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization.

Iacono P, Parodi MB, Papayannis A, Kontadakis S, Sheth S, Cascavilla ML, Bandello F.

Retina. 2012 Sep;32(8):1539-46. doi: 10.1097/IAE.0b013e31826956b7.

PMID:
22922846
9.

Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization.

Ruiz-Moreno JM, Montero JA, Arias L, Araiz J, Gomez-Ulla F, Silva R, Piñero DP.

Retina. 2010 Nov-Dec;30(10):1609-15. doi: 10.1097/IAE.0b013e3181e22659.

PMID:
20856171
10.

Different dosing of intravitreal bevacizumab for choroidal neovascularization because of pathologic myopia.

Wakabayashi T, Ikuno Y, Gomi F.

Retina. 2011 May;31(5):880-6. doi: 10.1097/IAE.0b013e3181f2a293.

PMID:
21242860
11.

Results of 1-year follow-up examinations after intravitreal bevacizumab administration for idiopathic choroidal neovascularization.

Inoue M, Kadonosono K, Watanabe Y, Sato S, Kobayashi S, Yamane S, Ito R, Arakawa A.

Retina. 2010 May;30(5):733-8. doi: 10.1097/IAE.0b013e3181c9699c.

PMID:
20168271
12.

Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study.

Chan WM, Lai TY, Liu DT, Lam DS.

Br J Ophthalmol. 2009 Feb;93(2):150-4. doi: 10.1136/bjo.2008.145797. Epub 2008 Sep 18.

PMID:
18801766
13.

Myopic choroidal neovascularization treated by intravitreal bevacizumab: comparison of two different initial doses.

Ruiz-Moreno JM, Montero JA, Amat-Peral P.

Graefes Arch Clin Exp Ophthalmol. 2011 Apr;249(4):595-9. doi: 10.1007/s00417-010-1599-z. Epub 2011 Jan 14.

PMID:
21234588
14.

Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia.

Lai TY, Chan WM, Liu DT, Lam DS.

Retina. 2009 Jun;29(6):750-6. doi: 10.1097/IAE.0b013e31819ed6bd.

PMID:
19357555
15.

Intravitreal bevacizumab (Avastin) as primary treatment for myopic choroidal neovascularization.

Mandal S, Venkatesh P, Sampangi R, Garg S.

Eur J Ophthalmol. 2007 Jul-Aug;17(4):620-6.

PMID:
17671940
16.

Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial.

Zhang H, Liu ZL, Sun P, Gu F.

Am J Ophthalmol. 2012 Feb;153(2):300-306.e1. doi: 10.1016/j.ajo.2011.07.019. Epub 2011 Oct 6.

PMID:
21982109
17.

Intravitreal injection of 2.5 mg bevacizumab for treatment of myopic choroidal neovascularization in treatment-naive cases: a 2-year follow-up.

Chen CH, Wu PC, Chen YJ, Liu YC, Kuo HK.

J Ocul Pharmacol Ther. 2011 Aug;27(4):395-400. doi: 10.1089/jop.2011.0023. Epub 2011 Jul 19.

PMID:
21770740
18.

Multifocal electrophysiologic findings after intravitreal bevacizumab (avastin) treatment.

Torres-Soriano ME, Cubas-Lorenzo V, García-Aguirre G, Hernández-Rojas M, Kon-Jara V, Díaz-Rubio J, Fromow-Guerra J, Quiroz-Mercado H, Jiménez-Sierra JM.

Retina. 2012 May;32(5):972-6. doi: 10.1097/IAE.0b013e318229b1de.

PMID:
22105506
19.

Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.

Arevalo JF, Fromow-Guerra J, Sanchez JG, Maia M, Berrocal MH, Wu L, Saravia MJ, Costa RA; Pan-American Collaborative Retina Study Group.

Retina. 2008 Nov-Dec;28(10):1387-94. doi: 10.1097/IAE.0b013e3181884ff4.

PMID:
18827735
20.

Intravitreal bevacizumab as a treatment for choroidal neovascularisation secondary to myopia: 4-year study results.

Peiretti E, Vinci M, Fossarello M.

Can J Ophthalmol. 2012 Feb;47(1):28-33. doi: 10.1016/j.jcjo.2011.12.009.

PMID:
22333848
Items per page

Supplemental Content

Write to the Help Desk